graph Evidence gap map comparisons
atezolizumab based treatmentanti-PD-(L)1durvalumab based treatmentnivolumab based treatmentpembrolizumab based treatmentsintilimab based treatmentanti-PD-(L)1Immune checkpoint associationnivolumab plus ipilimumab
atezolizumab plus bevacizumab atezolizumab plus cabozantinib camrelizumab based treatment durvalumab plus bevacizumab nivolumab alone pembrolizumab alone pembrolizumab plus lenvatinib sintilimab Tislelizumab durvalumab plus tremelimumab nivolumab plus ipilimumab nivolumab plus ipilimumab plus SoC
mHCC - (neo)adjuvant (NA) 3       
mHCC - 1st line (L1) 10                     
mHCC - 2nd line (L2) 2    
Comparator:  vs Standard of Care (SoC);   vs nivolumab alone;   vs sorafenib;   vs placebo;   vs VEGF(R) inhibitor;   vs lenvatinib; 
Risk of bias:  low;   some concerns;   high;  NA;